Mark Patrick Keller

Title: Mark Patrick Keller: Innovator in Pharmaceutical Chemistry

Introduction

Mark Patrick Keller is a notable inventor based in McFarland, Wisconsin. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that target specific ailments. With a total of 5 patents, Keller's work has the potential to impact the treatment of various medical conditions.

Latest Patents

Keller's latest patents include innovative compounds such as benzoimidazole indolyl methanes, which are designed to inhibit PCSK9 and related ailments. These compounds are described as pharmaceutical compositions that can effectively target and treat conditions mediated by PCSK9. Another significant patent involves alpha/beta-polypeptide analogs of glucagon-like peptide 1 (GLP-1). These peptide analogs retain agonist activity while being more resistant to proteolytic degradation than native GLP-1. The analogs feature at least one α-amino acid replaced with a β-amino acid residue, which may be cyclically constrained. This advancement opens new avenues for diabetes treatment and the creation of more effective GLP-1 analogs.

Career Highlights

Throughout his career, Keller has worked with esteemed organizations such as the Wisconsin Alumni Research Foundation and Harvard College. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Keller has collaborated with notable colleagues, including Alan D. Attie and Samuel Helmer Gellman. These partnerships have enriched his research and led to significant advancements in pharmaceutical innovations.

Conclusion

Mark Patrick Keller's contributions to pharmaceutical chemistry through his patents and collaborations highlight his role as an influential inventor. His work continues to pave the way for new treatments and innovations in the medical field.